Huons Global said that it posted 449.4 billion won ($369.5 million) in sales in 2019, a 19 percent increase from 2018. The company also registered 72.9 billion won in operating profit, up 7 percent, over the cited period.

Huons headquarters in Seongnam, Gyeonggi Province

"Huons Global's core business divisions showed solid growth as its subsidiaries Huons and Humedix strengthened their management," the company said. "New products such as Liztox and Hihyalonce helped to drive the company's solid performance."

Huons alone recorded sales of 365 billion won, and an operating profit of 48.4 billion won in 2019, up 11 and 7 percent, respectively, compared to 2018.

"Huons' strong sales ere based on the robust sales of its circulatory and metabolic oral medications, which increased 19 percent from 2018," the company said. "The consignment business also grew 13 percent as the productivity of its eye drops improved thanks to the improved productivity of its manufacturing lines."

Sales growth in the dietary supplement business through subsidiaries, such as Huons Natural and Huons Nature, also supported the growth, the company added.

Humedix's growth was driven by solid growth in the flagship aesthetics division. The company recorded sales of 78.6 billion won and an operating profit of 13.3 billion won, marking increases of 21 and 24 percent, respectively, from 2018.

"Humedix's growth is attributed to the integrated marketing strategy of its aesthetic business, which includes Liztox, Hihyalonce, and Dermashine Series," the company said.

Huons Global stressed that Huons Medicare, an infection control company, also achieved strong sales of 34.9 billion won and operating profit of 6.2 billion won in 2019, thanks to eye drops and specialty medicines.

"Despite difficult economic conditions in the nation last year, each subsidiary strived to lay the foundation for sustainable growth by trying to strengthen the core competitiveness, diversify business lines, and expand the global business," Huons Vice Chairman Yoon Sung-tae said. "We will continue to grow this year by expanding the sales of new products, creating new business models based on open innovation, and strengthening international competitiveness."

corea022@docdocdoc.co.kr

<© Korea Biomedical Review, All rights reserved.>